Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Table 1

Summary of anthropometric and clinical parameters from patients with IBD at baseline (prior therapy) and endpoint (week 38).

IBD (N = 38)
Responsiveness to therapy	No response (NR group) (N = 7)		Partial response (PR group) (N = 11)		Full response (FR group) (N = 20)
	Baseline	Week 38	Baseline	Week 38	Baseline	Week 38
CRP (mg/l)	2.6; (0.7, 4.3); (ab)	4.3; (2.4, 7.5); (a)	5.7; (1.2, 8.9); (ab)	3.2; (0.55, 5.8); (ab)	3.5; (1.3, 17.3); (a)	0.9; (0.5, 1.5); (b)
WBC	6.7; (5.2, 9.4); (ab)	8.2; (6.8, 11.1); (a)	7; (5.8, 9); (ab)	6; (5.1, 7.5); (ab)	7.1; (5.3, 10); (ab)	5.9; (5.1, 6.4); (b)
PLT	269; (251, 373); (ab)	363; (279, 435); (a)	343; (290.5, 370.5); (ab)	283; (216, 379.5); (ab)	281; (243.5, 370); (ab)	209.8; (254, 282.5); (b)
Ferritin (µg/l)	31.59; (16.4, 55.6); (a)	30.9; (17.2, 55.9); (a)	40.6; (13.7, 67.2); (a)	16.8; (6.7, 89.8); (a)	58.3; (14.6, 126.4); (a)	51.7; (15.6, 74.7); (a)
Hb (µg/l)	128; (127, 152); (a)	134; (130, 143); (a)	136; (128, 146.5); (a)	133; (111, 135); (a)	132.5; (112.8, 144.8); (a)	142.5; (132, 154.3); (a)
FC (µg/g)	455; (162, 1,737); (ab)	764; (279, 976); (ab)	662; (274, 1,055); (ab)	426.5; (171.8, 1,596); (a)	479; (163, 858); (a)	40; (20, 137.5); (b)
BMI	19.84; (19.57, 22.15); (a)	22; (21.8, 30.4); (a)	23.1; (20.8, 26.7); (a)	20.8; (20, 24); (a)	22.3; (20.8, 23.9); (a)	23.4; (21, 25); (a)
Clinical score; (pMayo)	8.0; (7.0, 9.0); (abc)	7.0; (7.0, 7.0); (ac)	6.5; (4.8, 7.5); (ab)	4.0; (2.0, 4.3); (c)	5.5; (2.5, 7.8); (ac)	0; (0, 0.8); (bc)
Clinical score; (HBI)	6.0; (1.0, 7.5); (ac)	5.0; (4.5, 6.0); (ab)	3.0; (1.0, 5.5); (abc)	4.0; (1.0, 6.5); (abc)	1.5; (0, 3.8); (b)	0.5; (0, 1.0); (c)
Age (years)	33 (25, 44) (a)		29 (24, 47) (a)		29 (25, 41) (a)
Gender (F, N)	7 (a)		9 (ab)		10 (b)
Smoking (N)	4 (a)		1 (b)		1 (b)
Diagnosis UC/CD (N)	2/5 (a)		3/8 (a)		7/13 (a)
Infliximab/adalimumab (N)	1/6 (a)		4/7 (a)		12/8 (a)
Immunosupressant agent (N)	2 (a)		7 (a)		11 (a)
Disease duration (years)	6 (1, 10) (a)		3 (2, 8) (a)		4 (1, 12.75) (a)
Age at diagnosis (years)	25 (17, 39) (a)		23 (21, 44) (a)		25.5 (20, 29.5) (a)
Disease location
CD_L1	0 (a)		4 (a)		6 (a)
CD_L2	0 (a)		0 (a)		4 (a)
CD_L3	5 (a)		1 (a)		6 (a)
UC_E1	0 (a)		2 (a)		1 (a)
UC_E2	0 (a)		2 (a)		1 (a)
UC_E3	2 (a)		2 (a)		2 (a)
Surgery history—resection (N)	1 (a)		2 (a)		1 (a)

In total, we collected serum samples from 38 IBD patients. Medians are reported with the first and third quartiles in parentheses. N, number of participants; CD, Crohn’s disease; UC, ulcerative colitis; HBI, Harvey–Bradshaw Index; pMayo, partial Mayo score; CRP, C-reactive protein; FC, fecal calprotectin; Hb, hemoglobin; PLT, platelet count; WBC, white blood cells; ns, not significant; Statistical differences between groups are depicted by letters at the level of . When same letter is present (e.g., a, a) in one row of the table, no statistical difference between group or time points is present. When two different letters are present (e.g., a, b) in the one row of the table, there is statistical difference between these observations at the level of .